The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with Smoldering Myeloma.
The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPY
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
DARATUMUMAB FOR PATIENTS WITH KIDNEY FAILURESparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEIsatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ISATUXIMAB DURING STEM CELL TRANSPLANTIsatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Mu...
ISATUXIMAB IN FRAIL PATIENTSIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...
ISATUXIMAB COMBINATION THERAPYPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILUREPost-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
POST-TRANSPLANT MAINTENANCE THERAPYSteroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
DARATUMUMAB AND LENALIDOMIDE FOR NDMM²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
DARATUMUMAB FOR PATIENTS WITH KIDNEY FAILURESparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEIsatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Mu...
ISATUXIMAB IN FRAIL PATIENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDESteroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
DARATUMUMAB AND LENALIDOMIDE FOR NDMM²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETIsatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ISATUXIMAB DURING STEM CELL TRANSPLANTIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...
ISATUXIMAB COMBINATION THERAPYPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDE²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...
ISATUXIMAB COMBINATION THERAPYPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDE²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma tags that are associated with this tag.
Bispecific Antibody
A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.
CAR T Cell
CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.
Monoclonal Antibody
Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.